Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
contrast agent
gadolinium-based contrast agent |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2011 (US) |
| gptkbp:ATCCode |
V08CA09
|
| gptkbp:brand |
gptkb:Gadovist
Gadavist |
| gptkbp:CASNumber |
138071-82-6
|
| gptkbp:chemicalClass |
macrocyclic
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:excretion |
renal
|
| gptkbp:halfLife |
1.8 hours
|
| gptkbp:hasMolecularFormula |
C18H31GdN4O9
|
| https://www.w3.org/2000/01/rdf-schema#label |
gadobutrol
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bayer_AG
|
| gptkbp:molecularWeight |
604.72 g/mol
|
| gptkbp:riskFactor |
gptkb:nephrogenic_systemic_fibrosis
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
dizziness headache allergic reaction |
| gptkbp:usedFor |
magnetic resonance imaging
|
| gptkbp:bfsParent |
gptkb:Gadovist
gptkb:gadolinium-based_contrast_agents |
| gptkbp:bfsLayer |
7
|